SCHEMBL4536087

SCHEMBL4536087

CC(C)(C)OC(=O)C(CCC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
LTA4H P09960 1/20 0.46
SYK P43405 1/20 0.45
LMNA P02545 1/20 0.44
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
PPARA Q07869 1/20 0.43
SLC15A1 P46059 1/20 0.42
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GAA P10253 1/20 0.41
CDC25B P30305 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18953153 1.00 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL4536083 1.00 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL28531197 0.96 ALDH1A1 (0.49) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL28525631 0.91 LTA4H (0.46) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL20943303 0.88 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL22465650 0.86 ALDH1A1 (0.45) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL24591298 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL8226793 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL24602777 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK
SCHEMBL12156576 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1LTA4HSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170237-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF UNIVERSITEIT GENT (BE) 2025-05-29 US disclosed
WO-2025027624-A1 CYCLIC GLYCOLIPOPEPTIDE VACCINE ADJUVANTS AND THE PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2025-02-06 WO disclosed
EP-4482849-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2025-01-01 EP disclosed
US-12134664-B2 Muramyl peptide derivatives BHARAT BIOTECH INTERNATIONAL LTD. (IN) 2024-11-05 US disclosed
WO-2023161962-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-08-31 WO disclosed
EP-3389643-B1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INT LTD (IN) 2023-05-03 EP disclosed
EP-3387005-B1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INT LTD (IN) 2022-08-24 EP disclosed
US-20220056080-A1 Muramyl Peptide Derivatives BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2022-02-24 US disclosed
US-10927147-B2 Muramyl peptide derivative compound, synthesis and uses thereof BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2021-02-23 US disclosed
US-10576147-B2 Muramyl peptide derivative compound, synthesis and uses thereof BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2020-03-03 US disclosed
CN-108884132-A Novel muramyl peptide derivative compound, its synthesis and application thereof 巴拉特生物技术国际有限公司 2018-11-23 CN disclosed
CN-108883080-A Novel muramyl peptide derivative compounds, their synthesis and use thereof 巴拉特生物技术国际有限公司 2018-11-23 CN disclosed
EP-3389643-A1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF Bharat Biotech International Limited (IN) 2018-10-24 EP disclosed
EP-3387005-A1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF Bharat Biotech International Limited (IN) 2018-10-17 EP disclosed
WO-2017103944-A1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2017-06-22 WO disclosed
WO-2017098529-A1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2017-06-15 WO disclosed
US-8946224-B2 Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions REDX PHARMA LIMITED (GB) 2015-02-03 US disclosed
EP-2638007-A2 DRUG DERIVATIVES Redx Pharma Limited (GB) 2013-09-18 EP disclosed
US-20130225594-A1 DRUG DERIVATIVES REDX PHARMA PLC (GB) 2013-08-29 US disclosed
WO-2012063085-A2 DRUG DERIVATIVES REDX PHARMA LIMITED (GB) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056080-A1 Muramyl Peptide Derivatives NOD2, NGLY1, LNPEP ALDH1A1 4849/4885L3MBTL1 3282/4885MAPK1 1159/4885
US-20130225594-A1 DRUG DERIVATIVES SQOR, NQO1, CYP2D6 ALDH1A1 76/4885L3MBTL1 4166/4885MAPK1 2849/4885
US-12134664-B2 Muramyl peptide derivatives NOD2, NGLY1, LNPEP ALDH1A1 4849/4885L3MBTL1 3282/4885MAPK1 1159/4885
US-10576147-B2 Muramyl peptide derivative compound, synthesis and uses thereof NOD2, HM13, QRFPR ALDH1A1 4868/4885L3MBTL1 2566/4885MAPK1 807/4885
US-20250170237-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF NOD2, NOD1, TLR9 ALDH1A1 4872/4885L3MBTL1 3516/4885MAPK1 2758/4885
US-10927147-B2 Muramyl peptide derivative compound, synthesis and uses thereof NOD2, TLR9, MICA ALDH1A1 4859/4885L3MBTL1 3921/4885MAPK1 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.